Project Description
XENIOS is a leader in technologies and therapies for the minimally invasive support of pulmonary and cardiac functions.
The novalung iLA, i-cor and medos products offer the full range of pulmonary and cardiac support on the basis of the unique XENIOS platform. The novalung iLA therapy can replace or complement harmful and immobilizing respiration treatments. The i-cor therapy supports cardiac function with a pulse that is synchronous with the human heartbeat. These minimally invasive therapies make it possible to provide cardiac and pulmonary support to patients who are awake, able to function on their own, and mobile. In addition, these therapies make it possible to avoid both damage to and infections in the lungs caused by artificial respiration, and the atrophy of the respiratory musculature.
2016
ZFHN sells its shares to Freseni
2013
Fusion of the two companies and founding of Xenios AG
2013
Investment by ZFHN in Medos Medizintechnik AG (manufacturer of systems for pumping blood)
2008
Investment by ZFHN in Novalung (manufacturer of artificial lungs)